Vernalis Research wins Queen’s Award for Enterprise
Vernalis is pleased to announce its Research group has won a Queen’s Award for Enterprise for outstanding achievement in International Trade. The Queen’s Award for Enterprise is the UK’s most prestigious business accolade, designed to recognise and encourage the achievements of UK businesses.
Vernalis’ Research group provides drug discovery expertise to pharmaceutical companies to develop novel treatments for unmet medical needs. Its scientists are recognised as world leaders in fragment and structure based drug discovery and have built a reputation for innovation and delivery. This expertise has been a key factor in securing strategic collaborations with non-UK pharmaceutical companies, resulting in significant growth in overseas revenues and earnings. Recent collaborators include Asahi Kasei Pharmaceuticals, Genentech, GSK, Lundbeck and Servier.
Ian Garland, Chief Executive Officer, commented, “Vernalis is absolutely delighted with this award which is a strong endorsement of both the talent and capabilities of our research group and recognition of the significant achievement in growing overseas
earnings in recent years.”
–ends —
Enquiries:
| Vernalis plc: | |
| Ian Garland, Chief Executive Officer | +44 (0) 118 938 0015 |
| David Mackney, Chief Financial Officer | |
| Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
| Lucy Tilley | |
| Dr Julian Feneley | |
| Henry Fitzgerald-O’Connor | |
| Shore Capital (Joint Broker) | +44 (0)20 7408 4090 |
| Bidhi Bhoma | |
| Toby Gibbs | |
| Brunswick Group: | +44 (0) 20 7404 5959 |
| Jon Coles |
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company’s technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company’s current expectations regarding future events including the clinical development and regulatory clearance of the Company’s products, the Company’s ability to find partners for the development and commercialisation of its products, as well as the Company’s future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
< Back to all news